Agilent Announces Thought Leader Award to Peter Neubauer

Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) announced that Dr. Peter Neubauer of the Technical University of Berlin has been awarded the prestigious Agilent Thought Leader Award for his innovative work in bioprocess engineering, focusing on developing new methods for more efficient bioprocess development, including genetic, cultivation, and analytical tools, with a particular focus on industrial-scale applications. The award will support his ongoing research into understanding and optimizing bioprocesses for difficult-to-express proteins and the development of scale-up/scale-down strategies.

Positive

• Dr. Neubauer's research focuses on optimizing bioprocesses for difficult-to-express proteins, and the development of scale-up/scale-down strategies, which has the potential to significantly improve pharmaceutical manufacturing processes and healthcare worldwide.

Negative

• None.

Technical University of Berlin researcher recognized for his innovative work in bioprocess engineering

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) announced that Dr. Peter Neubauer has been selected to receive a prestigious Agilent Thought Leader Award. As Chair of Bioprocess Engineering at the Technical University of Berlin, Dr. Neubauer leads innovative research to identify new methods for more efficient bioprocess development, including genetic, cultivation, and analytical tools, with a particular focus on industrial-scale applications.

Automation and high throughput are important for the real-time determination of critical quality attributes (CQAs), thus optimizing biotechnological applications. To this end, substantial resources are being directed toward developing process analytical technology (PAT) – a mechanism for designing, analyzing, and controlling pharmaceutical manufacturing processes by monitoring parameters that impact quality – to ultimately minimize public health risks.

Dr. Neubauer’s work orchestrates hardware, software, automation, mathematical models, and AI to discover optimal conditions for PAT end-to-end workflows. Integrating intelligent technologies and automation into PAT solutions is a key factor for moving the pharmaceutical industry toward optimized bioprocesses that improve safety and reduce hands-on intervention. The Agilent Thought Leader Award will support his ongoing research into understanding and optimizing bioprocesses for difficult-to-express proteins and the development of scale-up/scale-down strategies.

“We are truly grateful and excited that Agilent's award will open up the opportunity to incorporate two-dimensional liquid chromatography and mass spectrometry into our upcoming bioprocess laboratory. The use of such leading-edge instrumentation is a fundamental element in our journey towards achieving a higher level in automated bioprocess development,” said Dr. Neubauer who established and heads the KIWI-biolab as an International Future Laboratory for AI for Intelligent Integrated Biolaboratories. “Given our recent progress in seamlessly orchestrating all devices required in the process, ranging from extensive analyte-specific sample preparation to the management of big data, we feel ready to conquer this next logical step of integration.”

“Agilent is pleased to grant this Thought Leader Award to Dr. Neubauer to support his scientific developments in the biopharma space,” said Sudharshana Seshadri, vice president and general manager of Agilent’s Liquid Chromatography, Mass Spectrometry, and Automation Divisions, and executive sponsor of the award. “His important work will help the pharmaceutical industry optimize their bioprocesses and accelerate improved healthcare worldwide.”

The Agilent Thought Leader Award program promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis space. To learn more, visit the Agilent Thought Leader Award website.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230803578963/en/

MEDIA CONTACT

Naomi Goumillout

Agilent Technologies

+1.978.314.1862

naomi.goumillout@agilent.com

Source: Agilent Technologies Inc.

FAQ

What is the Agilent Thought Leader Award?

The Agilent Thought Leader Award is a program that promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis space.

What is Dr. Peter Neubauer's area of expertise?

Dr. Peter Neubauer specializes in bioprocess engineering, focusing on developing new methods for more efficient bioprocess development, including genetic, cultivation, and analytical tools, with a particular focus on industrial-scale applications.

How will the Agilent Thought Leader Award support Dr. Neubauer's research?

The award will support Dr. Neubauer's ongoing research into understanding and optimizing bioprocesses for difficult-to-express proteins and the development of scale-up/scale-down strategies.

What is the goal of Dr. Neubauer's research?

The goal of Dr. Neubauer's research is to optimize bioprocesses for difficult-to-express proteins and develop scale-up/scale-down strategies to improve pharmaceutical manufacturing processes and healthcare worldwide.